Atopic dermatitis or AD is an allergic disease that affects individuals of various ages. Recently, the IL‐4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has been reported to reduce several markers of AD, including the serum levels of thymus and activation‐regulated chemokine, blood lactate dehydrogenase or LDH, and serum total immunoglobulin E (IgE). The researchers and doctors retrospectively reviewed data from 40 AD patients who were treated with dupilumab. They assessed Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), body surface area or BSA scores, TARC, LDH, total IgE, and eosinophil count in peripheral blood for a total of 32 weeks.
The review showed that the EASI, IGA, and BSA scores improved significantly with treatment, indicating a reduction in the severity of AD. Serum TARC and LDH levels also significantly decreased with treatment. Serum IgE levels were unchanged at two weeks of treatment but considerably reduced between 4 and 32 weeks. The number of eosinophils in the peripheral blood decreased at 4, 16, and 32 weeks after treatment initiation. Several studies have reported that serum TARC, LDH, and total IgE levels are reduced by dupilumab treatment. Our real‐world data are the first to demonstrate a reduction in blood eosinophilia in patients who receive clinical treatment with dupilumab.
Ref: https://onlinelibrary.wiley.com/doi/10.1111/ijd.15183
